Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Fortress Biotech, Inc.: Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT | 80 | GlobeNewswire (Europe) | Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the... ► Artikel lesen | |
16.01. | Fortress Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
06.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease | 103 | GlobeNewswire (Europe) | Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones... ► Artikel lesen | |
FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
06.01. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
16.12.24 | Fortress Biotech, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
14.11.24 | Fortress Biotech GAAP EPS of -$0.76 misses by $0.17, revenue of $14.62M | 11 | Seeking Alpha | ||
14.11.24 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 146 | GlobeNewswire (Europe) | Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally... ► Artikel lesen | |
14.11.24 | Fortress Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
14.11.24 | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.11.24 | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
27.09.24 | Fortress Biotech files to sell 6.19M shares of common stock for holders | 16 | Seeking Alpha | ||
27.09.24 | Fortress Biotech, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
26.09.24 | Hedge Fund and Insider Trading News: Chris Hansen, David Tepper, Paul Singer, Steven Cohen, Platinum Asset Management, Elliott Investment Management, Millennium Management, Fortress Biotech Inc (FBIO), Crowdstrike Holdings Inc (CRWD), and More | 31 | Insider Monkey | ||
26.09.24 | Fortress Biotech, Inc.: Fortress Biotech to Participate in October 2024 Investor Conferences | 4 | GlobeNewswire (USA) | ||
23.09.24 | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
20.09.24 | Why Fortress Biotech (FBIO) Stock Is Getting Hammered | 7 | Benzinga.com | ||
20.09.24 | Fortress Biotech to sell 3.9M shares at $1.65 in registered direct offering | 1 | Seeking Alpha | ||
20.09.24 | Fortress Biotech secures $8 million in stock sales | 1 | Investing.com | ||
20.09.24 | Fortress Biotech sichert sich 8 Millionen US-Dollar durch Aktienverkäufe | 7 | Investing.com Deutsch | ||
20.09.24 | Fortress Biotech, Inc.: Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements | 4 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 57,19 | 0,00 % | Tempus AI's Options Frenzy: What You Need to Know | ||
EVOTEC | 8,580 | +5,66 % | BioTech - jetzt geht's los! 100 % Chancen für Evotec, BioNxt, Bayer, Formycon und Novo Nordisk! | Der DAX 40-Index erreichte in der letzten Woche mit 21.520 Punkten ein neues Allzeithoch. Das klingt auf den ersten Blick komisch, denn die Hälfte aller Werte krebst an mehrjährigen Tiefstständen. Zugpferde... ► Artikel lesen | |
TECTONIC THERAPEUTIC | 54,73 | 0,00 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 13,670 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,690 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
BIONTECH | 116,60 | +0,34 % | Nach Gates-Besuch: BioNTech-Aktie legt deutlich zu | Die Aktie von BioNTech hat am Donnerstag einen deutlichen Kurssprung hinlegen können. Unterstützung erhielt das Papier dabei vom Besuch des Microsoft-Gründers Bill Gates in dieser Woche. Zudem hat das... ► Artikel lesen | |
MODERNA | 40,315 | -3,59 % | Moderna Aktie: Finanzen im Fokus | Der US-Pharmakonzern Moderna hat einen bedeutenden Vertrag für die Belieferung der Europäischen Union mit seinem COVID-19-mRNA-Impfstoff abgeschlossen. Die Vereinbarung, die sich über einen Zeitraum... ► Artikel lesen | |
CG ONCOLOGY | 30,150 | -0,30 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
CARGO THERAPEUTICS | 3,390 | 0,00 % | Safety Risk Sinks Cargo Therapeutics' Cancer Cell Therapy Prospect, Leading to 50% Staff Cut | ||
89BIO | 9,650 | +10,54 % | 89bio, Inc. - 8-K, Current Report | ||
BB BIOTECH | 42,600 | +2,16 % | EQS-News: BB BIOTECH AG: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Jahresergebnis/Dividende
BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
24.01.2025 / 07:00 CET/CEST
Für... ► Artikel lesen | |
IMMUNOME | 10,510 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
VIR BIOTECHNOLOGY | 10,290 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
SUMMIT THERAPEUTICS | 22,320 | +3,14 % | Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? | ||
AVIDITY BIOSCIENCES | 32,630 | +2,10 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen |